Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France

“…In the EPICLIN study [26], in the subgroup of patients enrolled in France (n = 876), median PFS and OS for advanced NSCLC were 6.3 and 10.8 months, respectively. In the FRAME study [40], for advanced disease, median OS and PFS were 10.3 and 5.6 months, respectively. In the PIvOTAL study [41], a multinational retrospective cohort study aimed to describe real-world treatment patterns of 1,265 patients with advanced NSCLC who initiated first-line systemic therapy from January 2011 through June 2014, median OS in the 2 participating European countries (Italy and Spain) was 16.7 and 10.7, respectively.…”

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

“…With an assumption of 5% of unevaluable patients, the estimated total sample size of 1334 patients would allow the 95% CI for the median OS in the smallest cohort to have a width between 40 and 50% of the estimate; for example, if the median would fall at 8 months, the CI would not be greater than 4 months (about 6-10 months). This sample size was also considered sufficient for precision of the estimates in the secondary objectives including those previously published [12]. Since the planned duration of the observational period was 18 months, and based on the survival rates in this population, the follow-up duration was sufficient to provide reliable estimates for the median and 1-year survival probabilities.…”

“…Thus, the FRAME study [12] was designed as a European multicenter noninterventional, non-randomized prospective observational study to obtain real world data not otherwise accessible in a clinical trial setting.…”

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany

“…We assumed that all chemotherapies would be administered for up to six cycles [5], with the estimated distribution of these chemotherapies based on observed rates in Germany [27]. Dosing regimens were extracted from Rosell et al [17], and detailed information can be found in the referenced data.…”